A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
NCT ID: NCT06926621
Last Updated: 2026-01-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
PHASE2
36 participants
INTERVENTIONAL
2025-04-28
2028-07-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2
NCT06523400
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.
NCT06549400
Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy
NCT03692312
ANAVEX2-73 Study in Patients With Rett Syndrome
NCT03941444
Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old
NCT06769633
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VX-670
Participants will receive multiple doses of VX-670.
VX-670
Solution for intravenous administration.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VX-670
Solution for intravenous administration.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vertex Pharmaceuticals Incorporated
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wesley Research Institute
Auchenflower, , Australia
Neuroscience Clinical Trials Unit, Alfred Brain
Melbourne, , Australia
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg - Pulmonology
Leuven, , Belgium
Altasciences Montreal
Montreal, , Canada
Montreal Neurological Institute-Hospital
Montreal, , Canada
University of Ottawa
Ottawa, , Canada
Universite Laval - Neurology
Québec, , Canada
Hospital Universitario y Politecnico La Fe - Neurology
Valencia, , Spain
Queen Elizabeth University Hospital - Neurology
Glasgow, , United Kingdom
Leonard Wolfson Experimental Neurology Centre CRF
London, , United Kingdom
Royal Hallamshire Hospital - Neurology
Sheffield, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-517983-47-00
Identifier Type: OTHER
Identifier Source: secondary_id
VX24-670-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.